| Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.Nat Med | PMID 38191615无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study).JCO Glob Oncol | PMID 38237092PMC10805440 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.Lancet Rheumatol | PMID 38258678无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of influenza viral load in nasopharyngeal and midturbinate swabs.Influenza Other Respir Viruses | PMID 38260724PMC10800293 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation: A phase 3, randomized, placebo-controlled study.Rev Gastroenterol Mex (Engl Ed) | PMID 37225537无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study.Nephron | PMID 37473746PMC10794965 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Brain Injury Outcomes after Adjuvant Erythropoietin Neuroprotection for Moderate or Severe Neonatal Hypoxic-Ischemic Encephalopathy: A Report from the HEAL Trial.Dev Neurosci | PMID 37906983PMC11249061 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Tumor Shrinkage Pattern with Biweekly Triplet Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract Cancers: Implications for Neoadjuvant Therapy from the Data of KHBO1401 (KHBO1401-1A Study).Oncology | PMID 38048759PMC11152028 | 2024 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.Dermatology | PMID 38081155PMC10997245 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2.Am J Nephrol | PMID 38253036PMC11152003 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.J Alzheimers Dis | PMID 38427485PMC10977351 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].Zh Nevrol Psikhiatr Im S S Korsakova | PMID 38676683无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial.Cancer Treat Res Commun | PMID 38735220无 PMCID | 2024 | 0.95 | The trial is oncology, human, randomized, Phase IIIB, drug-intervention, and an original result report. However, it lacks a primary or key secondary time-to-event efficacy endpoint as defined (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The results focus on patient preference, administration time, and safety, making it ineligible. | 待处理 |
| Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3.Dermatology | PMID 38934147PMC11651339 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial.J Prev Alzheimers Dis | PMID 39044494PMC11266256 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease.J Prev Alzheimers Dis | PMID 39044495PMC11266366 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial.Digestion | PMID 39068917PMC11633862 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.Future Oncol | PMID 39072392PMC11485878 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).J Alzheimers Dis | PMID 39177596PMC11380290 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants.Expert Rev Vaccines | PMID 39279603无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial.Cancer Treat Res Commun | PMID 39305541无 PMCID | 2024 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer.Future Oncol | PMID 39324726PMC11537291 | 2024 | 0.90 | The document is an original report from a Phase III randomized trial, but its sole focus is a quality-of-life analysis. It does not contain or report the primary or key secondary time-to-event efficacy endpoints (OS, PFS, DFS, etc.) required for inclusion in this KM digitization cohort. | 待处理 |
| Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.J Prev Alzheimers Dis | PMID 39350371PMC11436400 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.Future Oncol | PMID 39360943PMC11572312 | 2024 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II).Immunotherapy | PMID 39781908PMC11759530 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of MDMA-assisted therapy for PTSD on self-experience.PLoS One | PMID 38198456PMC10781106 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.Front Immunol | PMID 38420129PMC10900843 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Abemaciclib as adjuvant treatment for high-risk early breast cancer.Farm Hosp | PMID 37735004无 PMCID | 2024 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.J Clin Lipidol | PMID 38341323无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19.Front Immunol | PMID 38694503PMC11061480 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®.Dermatitis | PMID 38108653无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis.Pediatr Dermatol | PMID 38413239无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of baseline factors with 1-year outcomes in the SB11-ranibizumab equivalence trial: A post hoc analysis.Asia Pac J Ophthalmol (Phila) | PMID 38759795无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical study.Indian Heart J | PMID 38871219PMC11329064 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China.Front Endocrinol (Lausanne) | PMID 38774225PMC11106447 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.Front Immunol | PMID 38827749PMC11143795 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.Front Immunol | PMID 38863717PMC11165140 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.Front Immunol | PMID 38903523PMC11187303 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cardiopulmonary Protection of Modified Remote Ischemic Preconditioning in Mitral Valve Replacement Surgery: A Randomized Controlled Trial.Cardiovasc Ther | PMID 39742012PMC11221996 | 2024 | 0.90 | The study is a randomized controlled trial in human patients undergoing mitral valve replacement surgery, but it is not an oncology trial. It investigates a non-drug intervention (remote ischemic preconditioning) for cardiopulmonary protection, and its primary endpoint is a biomarker (cardiac troponin I concentration), not a time-to-event efficacy outcome (e.g., OS, PFS, DFS). Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort. | 待处理 |
| Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial.Semin Thorac Cardiovasc Surg | PMID 36272526无 PMCID | 2024 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.Headache | PMID 38982666无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fixed dose combination of aspirin and pantoprazole: Results of a multicenter, comparative, randomized, double-blind, double dummy, phase III study in Indian patients.Indian Heart J | PMID 39009075PMC11451355 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.PLoS One | PMID 39042627PMC11265720 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.PLoS One | PMID 39079163PMC11285951 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial.Front Immunol | PMID 39136011PMC11317399 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.Front Immunol | PMID 39286253PMC11403248 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ-population-based follow-up of two cluster-randomized trials.Front Cell Infect Microbiol | PMID 39315334PMC11417099 | 2024 | 0.90 | The study is an oncology Phase III randomized trial with a drug intervention and original results, but it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The primary outcome is vaccine efficacy against cervical neoplasia, measured as relative risk reduction or incidence comparison, not survival analysis. | 待处理 |
| Efficacy and safety of Aurantii Fructus Immaturus flavonoid Tablets vs. domperidone for functional dyspepsia: a multicenter, double-blind, double-dummy, randomized controlled phase III trial.Acta Gastroenterol Belg | PMID 39745035无 PMCID | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes.Pediatr Diabetes | PMID 40302969PMC12016772 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD.Int J Chron Obstruct Pulmon Dis | PMID 39429809PMC11491098 | 2024 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |